This particular study with 125 patients with codrituzumab failed to show any significant improvement of the median progression-free survival and overall survival, even though those patients had high CD16/FcγRIIIa expression on peripheral immune cells and GPC3 expression in the tumor. This evidence concerns the gene GPC3 and neoplasm.